Active surveillance shows Zostavax safe with other vaccines
Researchers have analysed data from the first few years of the national program for over-70s
People older than 70 who are given the live-attenuated herpes zoster vaccine Zostavax concomitant with another vaccine are at no greater risk of adverse events than those given the zoster vaccine alone, Australian researchers have found.
The findings, based on data collected by the AusVaxSafety active surveillance program, suggest that Zostavax can be safely administered alongside influenza, 23-valent pneumococcal or the diphtheria/tetanus vaccine.
AusVaxSafety, run by National Centre for Immunisation Research and Surveillance (NCIRS) in Sydney, sends follow